Jacob Muncie
About Jacob Muncie
Jacob Muncie is the Director of Clinical Quality Assurance at Bristol Myers Squibb, with over 30 years of experience in the pharmaceutical and biotechnology industries.
Title
Jacob Muncie currently holds the position of Director, Clinical Quality Assurance at Bristol Myers Squibb in Princeton, New Jersey, United States. In his career, he has also served as Associate Director and Director at Celgene, located in Summit, New Jersey.
Education and Expertise
Jacob Muncie earned a Bachelor of Arts (BA) in Biology from Thomas Edison State College. With over 30 years of experience in the pharmaceutical and biotechnology industries, he specializes in clinical quality assurance and regulatory compliance.
Professional Background
Jacob Muncie has a comprehensive background in clinical quality assurance. He has significant experience working with major pharmaceutical companies. His career includes long-term positions such as a decade-long tenure at Bristol-Myers Squibb in Hopewell, NJ, and shorter roles at various companies, including ImClone Systems and Covance. He has demonstrated versatility by working both in large pharmaceutical corporations and smaller biotech firms.
Previous Roles
Muncie has held numerous influential roles throughout his career. Highlights include serving as Associate Director at Bristol-Myers Squibb, ImClone Systems, and Covance. His earlier career included senior auditor positions at Johnson & Johnson, Roche, Taylor Technology, and Pharmaco LSR (formerly Bio/dynamics Inc.). These roles have equipped him with a robust foundation in auditing and regulatory compliance.
Industry Experience
Jacob Muncie possesses extensive industry experience, working in various capacities from Senior Auditor to Director. His tenure at companies such as Roche and American Cyanamid, along with contributions to smaller firms like Bio/dynamics Inc., reflects his ability to adapt and lead in diverse organizational contexts. Muncie's extensive career reflects a strong commitment to ensuring clinical quality and regulatory adherence.